Seres Therapeutics, Inc.

NasdaqGS:MCRB Stock Report

Market Cap: US$76.7m

Seres Therapeutics Management

Management criteria checks 3/4

Seres Therapeutics' CEO is Rich Kender, appointed in Mar 2026, has a tenure of less than a year. directly owns 0.033% of the company’s shares, worth $25.15K. The average tenure of the management team and the board of directors is 1.3 years and 8.8 years respectively.

Key information

Rich Kender

Chief executive officer

US$123.4k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.03%
Management average tenure1.3yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

Seeking Alpha • Feb 06

Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'

Summary Seres Therapeutics sold VOWST to Nestlé in 2024. This helped validate their microbiome therapeutics. This sale also helped them extend their runway into Q2 2026 after a 25% workforce reduction. Their next value driver will come with SER-155’s Phase 2 for gut-driven bloodstream infections in allo-HSCT patients. The initial Phase 1b showed 77% relative BSI risk reduction with favorable safety, and the FDA gave it a Breakthrough designation. MCRB’s valuation still looks relatively reasonable. But, as a thinly traded microcap, any dilution concerns are heightened. Thus, I think it’s better to rate it a “Hold” today. Read the full article on Seeking Alpha
Analysis Article • Nov 15

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

The Seres Therapeutics, Inc. ( NASDAQ:MCRB ) share price has fared very poorly over the last month, falling by a...
Seeking Alpha • Sep 23

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Summary Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also gets potential future milestone payments of up to $275 million. Promising Phase 1b data for SER-155 shows potential in preventing bacterial infections in immunocompromised patients, positioning it as a new value driver. Favorable SER-155 results and potential FDA Breakthrough Therapy Designation could expedite regulatory approval, enhancing MCRB's investment appeal. Despite selling its most valuable IP, MCRB's valuation now looks compelling, making it a speculative "buy" for investors aware of its inherent biotech and cash runway risks. Read the full article on Seeking Alpha
Analysis Article • Jul 13

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shares have continued their recent momentum with a 44% gain in the last month...
Analysis Article • May 08

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shares have had a really impressive month, gaining 46% after a shaky period...
Analysis Article • Mar 23

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Unfortunately for some shareholders, the Seres Therapeutics, Inc. ( NASDAQ:MCRB ) share price has dived 30% in the last...
Seeking Alpha • Jan 30

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Summary Seres Therapeutics focuses on microbiome therapies, with its leading product VOWST preventing recurrent Clostridioides difficile infection. The company is developing SER-155, which has FDA Fast Track Designation, and has other products in its pipeline for ulcerative colitis and oncology applications. Despite promising research, due to the company's financing concerns and heavy short interest, I rate it a "sell" for now. Still, I discourage shorting the shares as many potential unforeseen catalysts could squeeze the shares higher. I think shorting at this point is too risky. Read the full article on Seeking Alpha
Analysis Article • Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

To the annoyance of some shareholders, Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shares are down a considerable 30% in...
Analysis Article • Aug 31

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

The Seres Therapeutics, Inc. ( NASDAQ:MCRB ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Aug 09

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

CEO

Rich Kender (69 yo)

less than a year
Tenure
US$123,375
Compensation

Mr. Richard N. Kender, also known as Rich, BS, MBA, is Interim CEO & Executive Chair of Seres Therapeutics, Inc. from March 2, 2026 and has been its Director since October 2014 and was its Independent Dire...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Kender
Interim CEO & Executive Chairless than a yearUS$123.38k0.033%
$ 25.1k
Matthew Henn
President & Chief Scientific Officer7.3yrsUS$1.01m0.081%
$ 62.1k
Marella Thorell
Executive VP2.2yrsUS$1.11mno data
Thomas DesRosier
Executive VP10yrsUS$1.14m0.082%
$ 63.0k
Kelly Brady
Executive VP & COOless than a yearno data0.088%
$ 67.8k
Chris McChalicher
Executive VP & CTOless than a yearno datano data
Dennis Walling
Senior VP of Clinical Development & Head of Clinical Research1.3yrsno datano data
Ann Kurowski
Senior Vice President of Regulatory Affairs1.3yrsno datano data
1.3yrs
Average Tenure
58yo
Average Age

Experienced Management: MCRB's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Richard Kender
Interim CEO & Executive Chair11.6yrsUS$123.38k0.033%
$ 25.1k
Willard Dere
Independent Director8.8yrsUS$113.38k0.016%
$ 12.6k
Dennis Ausiello
Independent Director11.1yrsUS$131.69k0%
$ 0
Kurt Graves
Independent Director10.5yrsUS$88.38k0%
$ 0
Claire Fraser-Liggett
Independent Director3.3yrsUS$151.69k0%
$ 0
Eric Shaff
Director7.3yrsUS$2.07m0.12%
$ 95.4k
Andrew Goodman
Member of Scientific Advisory Boardno datano datano data
Curtis Huttenhower
Member of Scientific Advisory Boardno datano datano data
Stephen Berenson
Independent Director6.8yrsUS$168.99k0.0019%
$ 1.4k
Marcel van den Brink
Member of Scientific Advisory Boardno datano datano data
Cynthia Sears
Member of Scientific advisory boardno datano datano data
Jackie Papkoff
Member of Scientific advisory boardno datano datano data
8.8yrs
Average Tenure
69yo
Average Age

Experienced Board: MCRB's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 20:06
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seres Therapeutics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
John NewmanCanaccord Genuity
John TannerCantor Fitzgerald & Co.